Business Context and Reporting Period
This Form 8-K filing by Indaptus Therapeutics, Inc. (INDP) was submitted on January 8, 2026. The report details a corporate governance change involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: David Natan was appointed as a Class II director, effective January 8, 2026. His term expires at the 2026 annual meeting of stockholders.
- Committee Assignment: Mr. Natan was appointed to the Audit Committee, replacing Mr. Avraham Ben-Tzvi. Mr. Ben-Tzvi will remain on the Board and is intended to be engaged as a paid consultant.
- Independence: The Board determined that Mr. Natan satisfies the definition of an "independent director" and meets the heightened independence standards for Audit Committee service under NASDAQ listing standards.
Guidance, Outlook, and Management Commentary
The filing does not contain financial guidance, outlook, or general management commentary regarding business operations. The appointment of Mr. Natan was designated by Mr. David E. Lazar in exercise of his right to recommend three individuals to the Board under a securities purchase agreement dated December 22, 2025. Mr. Natan will participate in the Company's non-employee director compensation plan.
Key Facts for Investor Verification
- Verify the terms of the securities purchase agreement dated December 22, 2025, which granted Mr. David E. Lazar the right to nominate board members.
- Review the Non-Employee Director Compensation Program (Exhibit 10.1) to understand the financial implications of the new appointment.
- Confirm the status of Mr. Avraham Ben-Tzvi's transition from Audit Committee Chair to paid consultant while remaining a director.
- Assess Mr. Natan's background, including his experience as CEO of ForceField Energy, Inc., and his current roles at Sunshine Biopharma, Inc. and FIEE, Inc.